Polatuzumab vedotin (solution)
Based on 1 publication(s) in Google Scholar
Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.40%
- CAS 番号: 1313206-42-6
- 分子量:150000 (average)
-
保管条件:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Polatuzumab vedotin (solution)
More
生物活性
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 1313206-42-6
-
性状 Liquid
-
分子量 150000 (average)
-
Color Colorless to light yellow
-
SMILES
[Polatuzumab vedotin (solution)]
-
輸送条件
Shipping with dry ice.
-
保管条件
-80°C, protect from light
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Anal Chem
Direct Visualization and Quantitative Modeling of Mass Transport Limitation in Biomolecular Kinetics via Imaging-Based Meta-SPR. [Abstract]2026 Mar 24;98(11):8382-8393. PMID: 41814478
純度とドキュメンテーション
-
データシート (265 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Liebers N, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021 Jul 13;5(13):2707-2716. [Content Brief]
[2]. Li D, et al. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin. Br J Pharmacol. 2019 Oct;176(19):3805-3818. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Polatuzumab vedotin (solution) 関連分類
HY-132253A 関連分類
Powered by Bioz